IDRA 21
| 製品名 | IDRA 21 |
|---|---|
| CAS番号 | 22503-72-6 |
| 分子式 | C8H10N2O2S |
| 分子量 | 198.24 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 純度 | ≥98%(HPLC) |
| 溶解度 | Soluble in DMSO, methanol; slightly soluble in water |
| ストレージ | Store at -20°C, protected from light |
| パッケージ | 10 mg, 50 mg, 100 mg, 500 mg, 1 g |
お困りですか? 弊社チームまでお問い合わせください

同義語: IDRA 21, 7,8-dihydro-8-oxo-7-(2-hydroxyethyl)-9H-purine-6-carboxaldehyde, 7,8-dihydro-8-oxo-7-(2-hydroxyethyl)guanine, 8-oxo-7-(2-hydroxyethyl)guanine, 22503-72-6
IDRA 21 is a synthetic purine derivative that has garnered attention in neuropharmacology as a positive allosteric modulator of the AMPA receptor. Its chemical structure, featuring a 7,8-dihydro-8-oxo-purine core with a 2-hydroxyethyl side chain, distinguishes it from other AMPA receptor modulators and contributes to its unique pharmacological profile. While not a natural product, IDRA 21 is often studied alongside endogenous purines due to its structural similarity to guanine derivatives.
Initially identified through screening efforts aimed at finding cognitive enhancers, IDRA 21 has become a valuable tool compound for investigating glutamatergic signaling. Unlike direct AMPA receptor agonists, it modulates receptor activity by slowing desensitization, thereby enhancing synaptic responses without inducing excitotoxicity. This mechanism has positioned it as a candidate for addressing cognitive deficits in neurological disorders.
In research settings, IDRA 21 is primarily used to probe the role of AMPA receptors in learning and memory processes. Its ability to cross the blood-brain barrier and its favorable pharmacokinetic profile in animal models make it a subject of interest for preclinical studies. While not yet approved for clinical use, IDRA 21 continues to be a reference compound in the development of next-generation cognitive enhancers.
| パラメータ | 仕様 |
|---|---|
| 分析(HPLC) | ≥98.0% |
| 識別 | NMR, MS conform to structure |
| 乾燥減量 | ≤0.5% |
| 焼失残渣 | ≤0.11 TP3T |
| 重金属 | 10 ppm以下 |
| Microbial Limits | Total aerobic count ≤1000 CFU/g |